Oral glucose tolerance test performance in olanzapine ‐treated schizophrenia‐spectrum patients is predicted by BMI and triglycerides but not olanzapine dose or duration
ConclusionsOur data suggest that BMI and triglycerides may be implicated in olanzapine‐related glucoregulatory abnormalities. The lack of correlation between glucoregulatory abnormalities and olanzapine dose or treatment duration suggests preexisting metabolic disturbances and/or disturbances arising early in the course of treatment. Clinicians prescribing antipsychotics should consider oGTT, especially in patients with obesity and/or hypertriglyceridemia.
Source: Human Psychopharmacology: Clinical and Experimental - Category: Psychiatry Authors: Jeffrey Guina, Sayon Roy, Ankur Gupta, Daniel D. Langleben, Igor Elman Tags: RESEARCH ARTICLE Source Type: research
More News: Cholesterol | Diabetes | Eating Disorders & Weight Management | Endocrinology | Insulin | Obesity | Psychiatry | Schizophrenia | Study | Zyprexa